Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Hantavirus Protein Structure is Promising Drug Design Model

By Drug Discovery Trends Editor | February 29, 2016

Left: Hexameric rings form a tube of viral capsid. Right: view from the other side of the protein oligomer. Source:  Daniel Olal/MDCBank voles are small rodents that are not dangerous by themselves, but their excreta can contain one of the dangerous hantaviruses. While bank voles are unaffected by the infection, hantaviruses can cause potentially fatal diseases in humans for which no treatments exist. In central and northern Europe, infection is accompanied by fever, headache, or even renal failure. The strain that occurs in East Asia — the Hantaan virus — is even more dangerous: up to five percent of infected patients die of hemorrhagic fever, renal failure, or severe respiratory disorders.

Dr. Daniel Olal and Prof. Oliver Daumke of the MDC in Berlin have now analyzed the nucleoprotein of the Hantaan virus by means of X-ray crystallography and identified its three-dimensional structure. Olal and Daumke have worked out how individual nucleoproteins oligomerize in the presence of RNA molecules, and they have found hexameric circular complexes. “We already know about cellular defense mechanisms that inhibit viral growth. We think that the circular structures we have identified could play a part in this,” says Olal.

The nucleoprotein plays an important part in replication of the viral genome. If its function is disrupted, the cell cannot produce functional virus particles. This protein is therefore an ideal target structure for future drugs. “Our structure could be useful for the design of small molecules that specifically block the nucleoprotein,” says Olal. The researchers have identified three binding pockets on the surface of the protein that could serve as docking sites for such compounds. Olal is positive that such drugs will be developed in the future: “After all, the technology for finding candidates for drug development is getting better all the time.”

Source: Max Delbruck Center for Molecular Medicine


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE